Canaccord analyst William Plovanic lowered the firm’s price target on Nevro to $57 from $68 and keeps a Buy rating on the shares. The firm said with the sales organization overhaul, management is messaging it will likely take six to nine months for sales reps to become productive again.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVRO: